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Direct optic nerve sheath (DONS) application of
Schwann cells prolongs retinal ganglion cell survival
in vivo
L Guo*,1, B Davis1, S Nizari1, EM Normando1,2, H Shi3,4, J Galvao1, L Turner1, J Shi5, M Clements6, S Parrinello6 and MF Cordeiro1,2
Cell-based therapies are increasingly recognized as a potential strategy to treat retinal neurodegenerative disease.
Their administration, however, is normally indirect and complex, often with an inability to assess in real time their effects on
cell death and their migration/integration into the host retina. In the present study, using a partial optic nerve transection (pONT) rat
model, we describe a new method of Schwann cell (SC) delivery (direct application to injured optic nerve sheath, SC/DONS), which
was compared with intravitreal SC delivery (SC/IVT). Both SC/DONS and SC/IVT were able to be assessed in vivo using imaging to
visualize retinal ganglion cell (RGC) apoptosis and SC retinal integration. RGC death in the pONT model was best fitted to the
one-phase exponential decay model. Although both SC/DONS and SC/IVT altered the temporal course of RGC degeneration in
pONT, SC/DONS resulted in delayed but long-lasting effects on RGC protection, compared with SC/IVT treatment. In addition, their
effects on primary and secondary degeneration, and axonal regeneration, were also investigated, by histology, whole retinal
counting, and modelling of RGC loss. SC/DONS was found to significantly reduce RGC apoptosis in vivo and significantly increase
RGC survival by targeting secondary rather than primary degeneration. Both SC/DONS and SC/IVT were found to promote RGC
axonal regrowth after optic nerve injury, with evidence of GAP-43 expression in RGC somas and axons. SC/DONS may have the
potential in the treatment of optic neuropathies, such as glaucoma. We show that SC transplantation can be monitored in real time
and that the protective effects of SCs are associated with targeting secondary degeneration, with implications for translating
cell-based therapies to the clinic.
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In the central (CNS) and peripheral (PNS) nervous systems,
injury from initial lesions can lead to widespread damage to
neurons beyond the primary injury site; a phenomenon known
as ‘secondary degeneration’. Studies in spinal cord injury
have revealed secondary rather than primary degeneration to
be the major contributor to neuronal death and functional
impairment, and it is increasingly recognized as a therapeutic
target.1,2 Secondary degeneration also occurs in optic
neuropathies, including glaucoma, ischaemic optic neuro-
pathy, and Leber’s hereditary optic neuropathy.3–5 Retinal
neuronal loss in these conditions is reported to occur long after
the initial insult,6 implying that secondary mechanisms may
have an important role in optic neuropathic damage and that
targeting of secondary neuronal loss may represent a novel
therapeutic strategy.
Partial optic nerve transection (pONT) represents a reliable
and reproducible model for studying secondary degeneration, in
which a primary lesion is only made to dorsal axons and leaves
those in ventral optic nerve (ON) intact but vulnerable to
secondary degeneration.4,7 Secondary degeneration is thought
to be initiated by a cascade of reactive metabolic events,
including glutamate excitotoxicity, Ca2+ overload, excess free
radical formation, oxidative stress, mitochondrial dysfunction,
and increasedproteoglycanexpression, leading to cell death.7–14
Activated astrocytes are reported to be a major contributor to
spreading and acceleration of secondary degeneration.8,9
As in most CNS pathways, the mature ON possesses only a
limited ability to repair itself after injury, resulting in permanent
vision loss due to the death of retinal ganglion cells (RGCs),
the retinal output neurons that transmit visual information to
the brain.15 Compared with the CNS, the PNS has a
remarkable ability to regrow after injury, a process in which
Schwann cells (SCs) are thought to have a key role.16,17
SCs are the principal glia of the PNS and support normal
neuronal function.18,19 Upon axonal injury, SCs are reported to
shed their myelin sheaths and de-differentiate into progenitor
stem cells, which are capable of replacing damaged tissue
and providing a permissive environment for neuronal survival
and axonal regrowth.18,19 SCs are believed to achieve this
through releasing neurotrophic factors and producing cell
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adhesion molecules and extracellular matrix components.20
The neuroprotective and regenerative mechanisms between
SCs and neurons are thought to operate on a local basis via
adhesion molecules, allowing contact-mediated signalling
between cells,16,17,20,21 and extracellular free ligands, facil-
itating specific binding to the receptors in the target
neurons.16,17,20 However, a novel regulatory mechanism has
emerged, representing a more efficient and advanced com-
munication machinery, that is, vesicular transfer between SCs
and axons.16 We have recently demonstrated that the highly
efficient response of SCs to PN injury is triggered by Ephrin-B/
EphB2 signalling in fibroblasts, which guide SC sorting and
migration during nerve repair.21
Due to the regenerative ability of SCs in PNS repair,
transplantation of SCs to the injured ON has been previously
attempted.22–28 To date, however, the protective effects of SCs
on retinal neurons have been only assessed after either
intravitreal administration or suturing artificial SC grafts onto
transected ON, using postmortem histological observations,
with incomplete delineation of the mechanisms involved.22–28
Here we use a pONT model to investigate a new method of
SC delivery (direct application to injured ON sheath, SC/
DONS), using in vivo imaging and histological techniques, and
compare its effects on RGC apoptosis and loss to intravitreal
SC delivery (SC/IVT). Furthermore, we analysewhether these
actions target primary or secondary degeneration, to deter-
mine their potential in the treatment of optic neuropathy.
Results
SC/DONS reduces in vivo RGC apoptosis. To minimize
invasive procedures, SC/DONS was only made once during
the surgery of pONT. SCs (2×108cells/ml) were mixed with
Matrigel in a 1 : 1 ratio immediately before application, and 5 μl
of the mixture was administered onto the injured ON at the end
of pONT surgery (Figure 1). Having previously shown that ON
injury can be evaluated in vivo using DARC (Detection of
Apoptotic Retinal Cells),29 we first assessed the effects of SC/
DONS with the same method in pONT. Compared with
baseline (Figures 2a and b), untreated pONT induced a
significant increase in RGC apoptosis at both 7 (Figure 2c,
maximal level) and 21 (Figure 2d) days (Figure 2g, Po0.01),
which was similar to our previous study.29 SC/DONS
significantly reduced RGC apoptosis at both 7 (Figures 2e,
g–h, Po0.01) and 21 (Figures 2f, g–h, Po0.05) days
compared with untreated pONT. In this experiment, the
percentage of RGC apoptosis relative to SC/IVT could not
be evaluated due to an overlap of the fluorescence spectra of
green fluorescent protein (GFP)-SCs and apoptotic RGCs
labelled with annexinV-488. In addition, this study only
assessed SC effects following one application during pONT
surgery, in order to minimize the number of invasive and
anaesthetic procedures. However, to prolong therapeutic
efficacy and to mimic the clinical situation, we recognize the
need to assess different time points of DONS application. This
is to be the subject of future work.
Establishment and validation of a novel algorithm for
RGC count. Brn-3a-positive-stained cells were visualized in
retinal whole mounts using confocal microscopy (Figures 3a–d).
Automated counts using the algorithm were compared with
that obtained manually with four trained observers on normal
whole retina, in 0.92mm2 retinal areas (n= 14). A correction
factor was applied to mitigate proportional bias in the
algorithm,30 from which a highly significant correlation
between the automated and manual RGC counts was
obtained (Figures 3e and f and Supplementary Figures S1a–
c, Pearson’s correlation coefficient=0.9860, Po0.0001,
R2=0.9722). With the algorithm counting, the total number
of RGCs in normal retina was 80 818±4919, and RGC density
was 2152±526 (cells/mm2), which are comparable to the
estimates from previous studies.30,31
SC/DONS enhances RGC survival relative to SC/IVT.
Using the validated algorithm, we next assessed the effects of
SC transplantation on RGC survival following pONT. RGC
density counts were used to create longitudinal profiles of RGC
loss following pONT, which was fitted to a one-phase exponential
decay model with plateau (Equation 1) (Figure 4a, red line).
y ¼ y0  Plateauð Þ:e kxð ÞþPlateau ð1Þ
SC/DONS significantly increased the plateau phase
(Figure 4a, black line) of the ratio of remaining RGC (Figures
4b, Po0.05) and RGC density from 21 (Figure 4d, Po0.01) to
56 (Figure 4e, Po0.05) days compared with pONTonly group.
This profile was next compared with that seen in SC/IVT, which
in comparison best fitted to a model of plateau followed by
a one-phase decay (Equation 2) (Figure 4a, blue line).
A significant protective effect was observed only at 7 days
with SC/IVT (Figure 4c, Po0.05), compared with pONTonly.
y ¼ Plateau þ y0  Plateauð Þ:e K : xx0ð Þð ÞþPlateau ð2Þ
To ensure that protective effects on RGCs were a result of
SC-mediated neuroprotection rather than Matrigel (for DONS)
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Figure 1 Diagram of administrations of SCs in pONT. Schematic diagram shows
SC/DONS and SC/IVT transplantation of SCs in a rat pONT model. SCs were
administered directly to the ON sheath in the SC/DONS application after pONT
(0.2 mm cut was made in the dorsal optic nerve), whereas with SC/IVT SCs were
injected into the vitreous 3 days before pONT
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or culture medium (for IVT) derived growth factors; the effects
of vehicle on RGC survival following pONT were assessed
parallel to the treatments of SC/DONS and SC/IVT. Both
Matrigel and culture medium treatments were shown to have
no significant protective effect, compared with pONT only
animals (Supplementary Figures S2a and b, P40.05). By
contrast, both SC/DONS and SC/IVT resulted in a significant
increase on RGC density compared with pONT only
(Supplementary Figures S2a and b, Po0.01, Po0.05).
SC/DONS predominantly target RGC secondary degen-
eration with prolonged effects compared with SC/IVT.
Having established that SCs promoted RGC survival after
pONT, we next investigated whether the protective effects
were associated with inhibiting primary or secondary degen-
eration. pONT injures the dorsal ON fibres, inducing RGC
primary degeneration in the superior retina, while the RGCs in
the central and inferior retina survive the initial insult but
are vulnerable to secondary degeneration.4,7 To separate
primary and secondary events and avoid bias in RGC counts,
retinal whole mounts were divided into the superior, central,
and inferior regions, and RGC densities were calculated for
each region (Figure 5a). In pONT only eyes, the longitudinal
profiles of RGC loss in all three regions best fit to a one-phase
exponential decay model (Equation 1), with a slight
but not significant increase in half-lives of 5.5, 5.8 and 6.1 days
and plateaus of 443.1, 481.9 and 533.5 in the superior, central,
and inferior retina, respectively (P40.05, Figure 5b).
RGC profiles (RGC density and the ratio of RGCs remaining
to normal controls) in SC/DONS fitted to a one-phase
exponential decay model in all three regions (Figures 5c–e,
black line), demonstrating significantly greater protection in the
late stages, with a significant increase in the plateau phase in all
three regions (Figures 5f–h,Po0.05). In comparison, SC/IVT in
the central and inferior regions (Figures 5d and e, blue line) was
best fitted to a model of plateau followed by a one-phase decay
(Equation 2), in which a delayed loss of RGCswas observed in
the early stage followed by rapid RGC loss.
RGC survival was predominant in the central and inferior
regions, where RGCs are vulnerable to secondary degenera-
tion, but not in the superior region, where primary degenera-
tion is believed to be predominant (Supplementary Figure S3).
SC/DONS resulted in significant protective effects at 21 and
56 days (Supplementary Figures S3b and c, Po0.05,
Po0.01). In comparison, SC/IVT showed an early effect at
7 days until 21 days (Supplementary Figures S3d and e,
Po0.05). These results suggest that transplanted SCs mainly
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Figure 2 SC/DONS application of SCs reduces in vivo RGC apoptosis. RGC apoptosis was labelled by intravitreal injection of fluorescently-labelled annexin V and imaged
using a cSLO. Representative DARC images show RGC apoptosis (white spots) at baseline (a and b), pONTonly (c and d), and SC/DONS-treated pONT (pONT+SC/DONS,
e and f) at 7 (a, c, e), and 21 (b, d, f) days following treatment. pONT induced a significant increase of RGC apoptosis at 7 and 21 days, compared with normal control (g) and
SC/DONS treatment significantly reduced RGC apoptosis at both 7 and 21 days compared with untreated group (pONT) (g and h). Data were presented as means±S.E.
*Po0.05, **Po0.01
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affect secondary degeneration, and SC/DONS shows a
delayed but prolonged protective effect comparedwith SC/IVT.
Transplanted SCs integrate into the retina and ON and
promote axonal regrowth. To monitor the fate of SCs after
SC/IVT, imaging was performed in vivo using the HRA
(Heidelberg retina angiograph)+OCT (optical coherence
tomography) Spectralis. GFP-SCs were visualized for at
least 21 days in the vitreous, with most cells located around
the posterior capsule of the lens.32 A small proportion of the
cells migrated close to or on to the retina as early as 3 days
following transplantation (Figure 6a). By using the in vivo
cSLO (confocal scanning laser ophthalmoscopy) image
(Figure 6b) to define an area of interest, it is possible to
localize anatomically SC migration in the vitreous, closed to
the retina in an OCT-acquired optical section (Figure 6c).
GFP-SCs were migrating close to and integrating into the
retina at 21 days (arrows) but at a reduced number. These
in vivo observations were validated by confocal histology
(Figures 6e and f) where GFP-SCs are clearly visible in the
RGCL. With SC/DONS, SCs were observed to migrate into
the injured ON where they integrated within the axonal
bundles (Figure 6g). RGC axonal regrowth was identified in
the injured ON after SC/DONS (Figures 6h and i) and in the
retina (Figure 6j) following SC/IVT, which was consistent with
the overexpression of growth-associated protein (GAP)-43 in
the RGC soma (Figure 6k). In addition, co-localization of
regenerated axons and transplanted SCs was seen
(Figure 6j). RGC regeneration was not seen in control
animals with pONT only (data not shown).
Discussion
We have demonstrated a new approach to applying SCs
directly to the ON sheath (SC/DONS) and have shown it to
significantly reduce RGC apoptosis and prolong RGC survival
compared with IVT application following pONT in the rat. Our
results also show that transplanted SCs can be monitored
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Figure 3 SC effects on RGC survival after pONT can be evaluated using an algorithm on whole retinal mounts. RGCs in the whole retina were labelled with Brn-3a antibody
and imaged by confocal fluorescence microscopy. (a) Normal retina, (b) pONT retina, (c) pONT+SC/DONS retina, (d) pONT+SC/IVT retina, and (a1, b1, c1 and d1) represent
corresponding areas of high magnification images at 21 days following pONT. A substantial loss of RGCs was noted in the pONTonly retina (b and b1), compared with the normal
retina (a and a1), and SC/DONS treatment (c and c1) clearly reduced RGC loss. This increase in RGC survival was also seen in SC/IVT-treated eyes (d and d1). The number of
RGCs in retinal whole mounts was analysed using our newly established algorithm in ImageJ. To validate the algorithm, RGCs in 0.92 mm2 retinal sections were manually counted
by four trained individuals. (e) Correlation of algorithm output to average manual counting fitted a straight line with a correction factor based on a previous study30 (Pearson’s
correlation coefficient= 0.9860, Po0.0001, R2= 0.9722). (f) Bland–Altman plot shows good agreement between algorithm and manual counts after correction. Scale bars:
50 μm
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in vivo, and they are able to integrate into the RGCL and
injured ON, promoting RGC axonal regrowth. Finally, we show
that the protective effects of SCs are associated with targeting
secondary degeneration, with implications for translating cell-
based therapies to the clinic.
ON axotomy is often used to model optic neuropathies,4,5
which clinically are a leading cause of irreversible blindness
due to degeneration and loss of RGCs. Such neuropathies
include glaucoma, ischaemic optic neuropathy, and Leber’s
hereditary optic neuropathy.3–5,33–35 Protection and regenera-
tion of RGCs and their axons following injury is a clear unmet
medical need.
Transplantation of SCs has been previously attempted
intravitreally or by grafting onto an axotomized ON, with
successful regrowth and enhanced RGC survival
histologically.20,23–26,36 However, these models involved
transplantation of SCs to a completely transected ON, in
which artificial SC grafts were inserted into the stumps of cut
ON.22–28 In the present study, we have attempted, for the first
time, to directly apply SCs to a partially transected ON sheath
in rat. We found that SCs, with the aid of Matrigel, enables not
only migration into the lesion site but also penetration and
integration into the injured ON. Matrigel, mainly comprising
laminin and collagen IV, has been shown to be supportive for
SC survival and elongation in vitro37 and in vivo,38 possibly
due to the presence of growth factors.39 However, Matrigel
alone was found not to protect against pONT-mediated RGC
degeneration, with no significant difference in RGC density
observed between pONTonly and pONT+Matrigel. Compared
with artificial grafts, the SC/DONS appears to be an easier and
potentially more practical way of treating ON injury, and
the protective effect is more significant than intravitreal
administration.
The ability to use real-time imaging methods to monitor
effects and efficacy of treatment, as shown in this study,
highlights the translatable aspects of the results. Previously,
we have only used DARC to assess complete axotomy29—but
interestingly, in that model, we also showed peak apoptosis to
occur at 7 days, suggesting a similar temporal profile and
course of RGC death. Similar results were found by Wang
et al.40 recently, using histological analysis in the same pONT
model, with peak RGC apoptosis at 1 week which gradually
decreased over 12 weeks. One study showed different results,
however, which may be attributed to different experimental
protocols. First, Levkovitch-Verbin et al.13 applied a milder
insult cutting the ON to a depth of 0.1 mm compared with
0.2 mm in this study and approximately 0.4 mm in the study by
Wang et al.40—we and the others have previously shown that
the extent of neurotoxicity is dependent on the magnitude of
the insult.41,42 Second, rat species and weights were
different.31 Finally, the method used to identify apoptosis also
differed: Hoechst staining in histological cross-sectional
samples in the study by Levkovitch-Verbin et al., indirect
estimate by Wang et al.,40 and the in vivo demonstration of
annexin V-positive cells used in our study.
Manual counting of total RGCs is time consuming, labor
intensive, and tedious, with potential vulnerability to bias.
Sampling counting of RGCs from selected areas of the retina
is therefore chosen by many researchers.4,7,40,43,44 However,
it is evident that considerable variability exists even if a
significant fraction of the retinal area (quadrants or hemi-
retinas) are being sampled.30 In the present study, we have
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Figure 4 SC/DONS application promotes RGC survival longer than SC/IVT. (a) RGC loss in pONT only (red line) and pONT+SC/DONS treatment (black line) fitted to a
one-phase exponential decay model with plateau (Equation 1), while pONT+SC/IVT treatment (blue line) fitted to a model of plateau followed by a one-phase decay (Equation 2).
(b) SC/DONS (but not SC/IVT) treatment significantly increased the plateau of RGC density, compared with the pONTonly group, suggesting a significant neuroprotective effect.
(c–e) SC/IVT treatment significantly increased RGC survival at 7 days (c) while SC/DONS treatment increased RGC survival at 21 (d) and 56 (e) days, compared with pONTonly.
Data were presented as means± S.E. *Po0.05; **Po0.01
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established a simple algorithm to automatically count RGCs in
the entire retina and have shown that the algorithm output is
comparable to manual counting. The total number of RGCs in
normal Dark Agouti (DA) rats obtained from the algorithm
count (80 431 cells) is comparable to other published
automated counts of 81 486 in SD rats, 87 229 in PVG rats31
and 97 609 in Wistar rats,30 and is also comparable to the
estimated total number of RGCs by sampling manual counts
of 87 8094 and 74 10445 in Wistar rats and 77 400 in SD rats.46
The variations of RGC counts in different studies can be
caused by both animal strains31 and methodologies, such as
RGC markers and sampling method employed.30
A general phenomenon shared by many forms of neurode-
generation is a continuous steady or exponential decline in
neuronal number over time.47,48 This one-hit model of cell
death has been proposed in inherited and acquired neuronal
degenerative diseases, with implications for therapeutic
strategies.47,48 Previous studies have attempted to apply an
exponential decay model to the RGC loss occurring in ON
crush and complete transection in Thy-1 CFP mice.49,50 Here
we report that RGC death in the pONT model is best fitted to
the one-phase exponential decay model. Our results reveal
that although both DONS and IVT transplantation routes of
SCs alter the temporal course of RGC degeneration in pONT,
they act in different ways: SC/DONS results in a significant
increase in the duration of the plateau phase (increasing RGC
survival) while SC/IVT delays the early phase of degeneration
followed by a rapid decay. The mechanisms behind the
difference are unknown, but the earlier effects of SC/IVT could
be due to them producing neurotrophic factors locally that
rapidly affect surrounding RGCs.20,27,28,51 Furthermore, the
short-lived duration (o56 days) of effect may be due to the
rapid decline in the SC number in the vitreous. The delayed but
long-lasting effects of SC/DONS could be attributed to their
interaction and signalling with injured RGC axons, as direct
contact of ON axons with living SCs has been shown to have
an important role in RGC survival and regeneration.52,53
Partial ONT provides a good model for studying secondary
degeneration,4,7,8,13,54–56 which is defined as occurring after
an initial insult, consisting of widespread neuronal loss and
severe functional impairment far in excess of the original
injury.1,55Limiting secondary degeneration following a primary
insult is practically the only option in chronic disease such
as glaucoma, where initially the patient is asymptomatic.57
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Figure 5 SC/DONS application promotes RGC survival by targeting secondary degeneration. (a) Confocal retinal whole-mount, stained with Brn-3a, was divided into the
superior, central, and inferior regions, and RGC density calculated for each region. (b) Profiles of pONT-induced RGC loss in the superior, central, and inferior retina fitted to one-
phase exponential decay model (Equation 1) and showed no significant difference among the three regions in half-lives and plateau, indicating that secondary degeneration
occurred almost simultaneously with primary damage. (c–e) The effects of SC transplantation on RGC density in the superior (c), central (d), and inferior (e) retina reveal that SC/
DONS showed more protection in the late stages, with a significant increase of plateau in the superior (f), central (g), and inferior (h) retina compared with the no treatment group.
In comparison, SC/IVT showed an early delay in RGC loss followed by a rapid decay in the central and inferior retina (d and e). Data were presented as means±S.E. *Po0.05
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We demonstrate that SCs improve RGC survival predomi-
nantly through inhibition of secondary rather than primary
degeneration, as evidenced by the significant preservation of
RGC density in the central and inferior but not the superior
retinal segment. To the best of our knowledge, this is the first
time that SC’s neruoprotective role in targeting secondary
degeneration has been demonstrated. This suggests that the
therapeutic potential of SC transplantation may be more
practical for translating to the patient, because clinical
management of chronic ON damage is aimed at reducing
secondary damage after the onset of disease.57,58
It appears in our study, that in untreated pONT, where RGC
degeneration in all three regions is best fitted to a one-phase
exponential decay model, the kinetics of RGC decline (i.e., the
plateau and half-life) are extremely similar among the three
regions. This suggests that secondary degeneration in this
model occurs almost simultaneously with the primary injury.
This is in agreement with several recent studies.9,13,14 Indeed,
secondary degeneration has been demonstrated to be an
early event after pONT, with evidence of rapid spread of
oxidative stress beyond the injury site within 5 min, and
increased production of reactive oxygen/nitrogen species and
mitochondrial changes reported by 24 h.9–11 Injury-induced
activation of astrocytes is attributed to the early event, properly
via spread of oxidative stress and amplification of calcium
signals throughout the ON vulnerable to secondary
degeneration.8,9,59 In support, Ca2+ channel blockers have
been shown to limit secondary degeneration, resulting in
reduced RGC death and preserved visual function.7,12,59 In
addition, therapeutic modulation of mitochondrial function by
red/near-infrared irradiation therapy shows reduced oxidative
stress and mitochondrial dysfunction in ON vulnerable to
secondary degeneration.11,60
In vivo monitoring of stem cells after transplantation is
essential for a better understanding of their migration/integra-
tion into the host tissue. Using clinically available instruments,
we demonstrate that this is achievable using in vivo retinal
imaging. More importantly, we have demonstrated the use of
OCT imaging in tracking the fate of clusters of transplanted
cells. The findings of the low efficiency of retinal graft integration
*
RGCL
Vitreous
120 m
Figure 6 Transplanted SCs can migrate and integrate into the retina and the optic nerve and promote RGC axonal growth. (a) In vivo cSLO image of GFP-SCs revealed a big
cluster of cells within vitreous cavity (*) 3 days following transplantation, with some cells appearing to elongate and migrate towards the retina. (b and c) Combining in vivo cSLO
(b) with OCT (c) technology allows anatomical localization of GFP-SCs with an ‘optical section’ defined by the cSLO image (SC cluster outlined with red circle, with position of
OCT slice indicated by green line, b) and visualized using the OCT (corresponding position shown by green line, c). (d) In vivo cSLO image shows GFP-SCs close to, with an
elongated morphology, and integrating within the retina at 21 days (arrows) but at a reduced number. (e and f) Confocal fluorescence microscopy of whole retinal mounts showing
GFP-SCs (green) integrating into the RGC layer (RGCL, Brn-3a labelled, red) at 3 (e) and 21 (f) days after pONT (yellow, arrows and z-stack image of the RGCL). Transplanted
cells appeared to become elongated at 21 days, similar to what is seen in vivo. (g) GFP-SCs (green) integrated and migrated in the injured optic nerve 21 days after SC/DONS
transplantation (inset: smaller magnification of the ON). (h and i) GAP-43-labelled newly growing axons (white) in an injured ON after SC transplantation at low (h) and high (i)
magnification. (j) Neurofilament-L-labelled regenerated axons (red) in the retina, showing co-localization (arrows) with transplanted GFP-SCs (green) 14 days following pONT.
The inset is a low magnification of the area showing the optic nerve head. (k) GAP-43-labelled RGCs (green) with neurofilament-L-labelled axons (red) 21 days following ON
injury and SC transplantation. Scale bars: 20 μm
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could be associated with specific barriers, such as reactive
gliosis, local inflammatory cells, and extracellular matrix
components, and targeting these barriers has the potential to
dramatically improve transplanted cell integration.61–64
In accordance with previous studies,22–28 we identify
SC-mediated RGC regeneration in both the injured ON and
retina. Furthermore, the proximity of transplanted cells and
re-growing axons observed in this study supports the notion
that physical contact of living SCs with injured RGCs promotes
axonal regeneration.53 In the PNS, effective communications
between injured nerve and local SCs are essential for nerve
regeneration, which relies on various regulatory mechanisms,
including neurotrophic factors, adhesion molecules, extra-
cellular free ligands, and transfer of vesicles from SCs to
axons.16,20 Themechanisms behind SC-mediatedRGCaxonal
regeneration observed in this study remain unknown, but it is
likely that SCs communicate with injured ON in a similar way to
that in the PNS.16 This is possibly the most viable explanation
as to why SC/DONS was more effective than SC/IVT at
preserving RGCs for a prolonged period in the pONT model.
Materials and Methods
Animals. Adult male Dark Agouti rats weighing 150–200 g were treated with
procedures approved by the UK Home Office and in compliance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research. All animals
(n= 105) were maintained in a 12-h light/12-h dark cycle with a room illuminance of
140–260 lux during the bright portion of the cycle. Animals were provided standard
food and water ad libitum.
pONT. All animals had pONT performed in the left eye, using a previously
described technique.4 Under general anaesthesia (GA), an incision was made in the
superior conjunctiva, and the ON sheath was exposed. A longitudinal slit was next
formed in the dura mater to expose the ON, and a 0.2-mm cut was made in the
dorsal ON, 2 mm behind the eye using an ophthalmic scalpel with a steel cutting
guard (Figure 1). Damage to major ophthalmic blood vessels was avoided and
verified at the end by ophthalmoscopy.
SC culture. A GFP-transfected SC line,21,65 originally derived from rat sciatic
nerve, was cultured in DMEM 1.0 g/l glucose medium supplemented with 3%
stripped and heat-inactivated foetal calf serum, 4 mM l-glutamine, 1 μM forskolin,
2 μg/ml gentamycin, 0.1 mg/ml Kanamycin, and 0.5 ng/ml Heregulin.21,65 Cells were
cultured at 37 °C in a humidified incubator with 5% CO2 until 80–90% confluency
before passaged using 0.25% Trypsin-EDTA.
SC transplantation. Two modes of SC application were assessed (Figure 1):
for SC/DONS application, SCs (2 × 108cells/ml) were mixed with Matrigel (BD
Biosciences, Bedford, UK) in a 1 : 1 ratio, and 5 μl of the mixture was applied to the
partially transected ON at the end of pONT surgery. For SC/IVT, 5 μl of SCs at
2.5 × 108 cells/ml were injected intraocularly 3 days before pONT surgery. The number
of cells administered was calculated based on previous studies elsewhere.26–28 In the
control groups, pONT was carried out either without any treatment or using vehicle
control. Animals were killed at 3, 7, 14, 21, and 56 days following pONT; 4–10 animals
were included in each treatment group at each time point.
In vivo imaging of RGC apoptosis with DARC. Animals with SC/DONS
treatment and untreated controls were imaged at baseline for RGC apoptosis before
pONT and at 3, 7, 14, 21, and 56 days after pONT using DARC.29,66–69 Briefly,
animals under GA were intravitreally injected with fluorescently labelled annexin as
previously described,29,66–69 2 hours before imaging with a cSLO (HRA Spectralis,
Heidelberg Engineering, Heidelberg, Germany). The retinal images were then
collected, and the number of apoptotic RGCs were manually counted by four trained
individuals masked to the treatment groups.66
In vivo imaging of SC survival and migration. To monitor SC (GFP-
labelled) fate after intravitreal transplantation, animals with SC/IVT transplantation
were imaged in vivo using a customized HRA+OCT Spectralis70 to spatially track
GFP-SCs for survival and migration with an argon laser wavelength of 488 nm.
Immunohistochemistry and confocal microscopy. After animals
were killed, both eyes were enucleated and fixed in fresh 4% paraformaldehyde at
4 °C overnight. Retinal whole mounts and ONs were then dissected. To assess
RGC survival, retinal whole mounts were stained with an anti-mouse Brn-3a mAb
(1 : 500, Merk Millipore, Darmstadt, Germany) and examined under confocal
microscopy (LSM 710, Carl Zeiss MicroImaging GmbH, Jena, Germany), to
generate a single plane maximum projection of the RGC layer in each retina.
Additionally, some retinas were stained with a GAP-43 anti-mouse mAb (1 : 200,
Santa Cruz Biotechnology, Inc., Heidelberg, Germany) and neurofilament-L anti-
rabbit mAb (1 : 200, New England Biolabs, Hitchin, UK) to assess newly growing
RGC axons. The paraffin-embedded ON was sectioned longitudinally and
immunostained with GAP-43 mAb (1 : 200) to identify regenerated axons. Confocal
microscopy was also used to visualize transplanted GFP-SC migration/integration.
Automated quantification of Brn-3a labelled RGCs in retinal
whole mounts. A newly established algorithm using ImageJ (National Institute of
Health, Bethesda, MD, USA) was used to objectively assess RGC counts in retinal
whole mounts. Briefly, a high-pass filter was applied to the 8-bit Brn-3a (Green)
channel to remove background followed by application of a 130 intensity threshold.
The ImageJ watershed algorithm was then used to separate touching particles. Only
the particles within 7–21 μm size range were counted based on RGC sizes previously
reported.30 To exclude blood vessels that also stained with Brn-3a, circularity of each
particle was determined using Equation 3 where A is the particle area and P is the
perimeter, and particles with circularityo0.7 were excluded from the final RGC count:
cir cular i ty ¼ 4p A
p2
 
ð3Þ
. To ensure the validity of the algorithm, counts obtained from the algorithm were
compared with manual counts in 0.92 mm2 retinal sections by four trained individuals
masked to the algorithm results. The algorithm counting could be further improved by
introduction of a correction factor (Equation 4), as previously described,30 where DA is
actual RGC density (RGC/mm2), DR is the reported RGC density, and A is the total
retinal area (mm2) (Equation 4).
DA ¼ DR  1:163ð Þ  245A ð4Þ
. To calculate RGC density (cells/mm
2), the area of each retina was measured using
ImageJ, and the algorithm counts were divided by retinal area (mm2). The ratio of the
average density of RGCs to untreated controls (0–1) was also used for assessing SC
treatment. To assess SC effects on primary and secondary degeneration, retinal
images were divided into three equal parts of the superior, central, and inferior retina
before RGC density was calculated for each region.
Statistical analysis. All data were analysed with the Student’s t-test or
one-way ANOVA as appropriate using GraphPad Prism 5 (GraphPad Software, Inc.,
La Jolla, CA, USA). The longitudinal profiles of RGC degeneration following pONT
and SC treatment were fitted with either a one-phase exponential decay model with
plateau (SC/DONS, Equation 1 in Results section) or a model of plateau followed by
a one-phase decay (SC/IVT, Equation 2 in Results section). Data were presented as
means± S.E., and Po0.05 was considered to be significant.
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